Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | SOCS1 |
| Gene Name: | SOCS1 |
| Protein Full Name: | Suppressor of cytokine signaling 1 |
| Alias: | JAK-binding protein;STAT-induced STAT inhibitor 1;Tec-interacting protein 3 |
| Mass (Da): | 23551 |
| Number AA: | 211 |
| UniProt ID: | O15524 |
| Locus ID: | 8651 |
| COSMIC ID: | SOCS1 |
| Gene location on chromosome: | 16p13.13 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 21877 |
| Percent of cancer specimens with mutations: | 0.33 |
| General distribution of mutations: | Multi-site |
| Location of most mutations: | Broad distribution of mutation sites with many point mutations and deletions, but only 1 insertion and 2 complex mutations across the entire protein. |
| Gene undergoes hypermethylation: | Hepatocellular carcinoma, hepatoblastoma, hepatitis C virus-associated chronic hepatitis and liver cirrhosis, brain tumor, head and neck squamous cell carcinoma, gastric carcinoma, pancreatic cancer, colorectal cancer, acute myeloid leukemia, multiple mye |
| Normal role description: | SOCS1 is a negative regulator of JAK signalling. It is involved in binding and inhibiting their signalling activities inresponse to cytokine stimulation. It also negatively regulates JNK signalling induced by TNFa by degrading ASK1. Loss of funtion mutations result in oncogenesis due to dysregulated signalling. |